{"transactions":[{"id":786084,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T20:05:03.000Z","date":"2026-05-07","kind":"grant","planned":false,"acquired":true,"shares":1265,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15985,"source":{"system":"sec-edgar","filing":"0001193125-26-216737","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/31791/000119312526216737/ownership.xml","form_type":"4"}},{"id":786083,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T20:05:03.000Z","date":"2026-05-07","kind":"grant","planned":false,"acquired":true,"shares":1015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control."}],"balance_after":14720,"source":{"system":"sec-edgar","filing":"0001193125-26-216737","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000119312526216737/ownership.xml","form_type":"4"}},{"id":1099985,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A-2 Convertible Preferred Stock","published_at":"2025-06-27T17:12:43.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":677,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to terms of the Merger Agreement, each share of the preferred stock that was outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares into which such shares of preferred stock are convertible immediately prior to the Effective Time, by (B) the Closing Amount; plus (ii) one CVR with respect to each Share into which such shares of preferred stock are convertible immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to terms of the Merger Agreement, each share of the preferred stock that was outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares into which such shares of preferred stock are convertible immediately prior to the Effective Time, by (B) the Closing Amount; plus (ii) one CVR with respect to each Share into which such shares of preferred stock are convertible immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to terms of the Merger Agreement, each share of the preferred stock that was outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares into which such shares of preferred stock are convertible immediately prior to the Effective Time, by (B) the Closing Amount; plus (ii) one CVR with respect to each Share into which such shares of preferred stock are convertible immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6770},"source":{"system":"sec-edgar","filing":"0000950170-25-091035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025091035/ownership.xml","form_type":"4"}},{"id":1099984,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:12:43.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-25-091035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025091035/ownership.xml","form_type":"4"}},{"id":1099983,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:12:43.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025091035/ownership.xml","form_type":"4"}},{"id":1099982,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:12:43.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.36,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-25-091035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025091035/ownership.xml","form_type":"4"}},{"id":1099981,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:12:43.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.45,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025091035/ownership.xml","form_type":"4"}},{"id":1099980,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:12:43.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.7,"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-25-091035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025091035/ownership.xml","form_type":"4"}},{"id":1099979,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:12:43.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":9.9,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000950170-25-091035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025091035/ownership.xml","form_type":"4"}},{"id":1099978,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:12:43.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":8.8,"underlying":"Common Stock","underlying_shares":2325},"source":{"system":"sec-edgar","filing":"0000950170-25-091035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025091035/ownership.xml","form_type":"4"}},{"id":1099977,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T17:12:43.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4650,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":6.4,"underlying":"Common Stock","underlying_shares":4650},"source":{"system":"sec-edgar","filing":"0000950170-25-091035","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025091035/ownership.xml","form_type":"4"}},{"id":1099976,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T17:12:43.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":67233,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, these Shares were converted into the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive  (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-091035","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025091035/ownership.xml","form_type":"4"}},{"id":1163157,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-01T20:05:11.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":1338,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13705,"source":{"system":"sec-edgar","filing":"0000950170-25-061816","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/31791/000095017025061816/ownership.xml","form_type":"4"}},{"id":1163156,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-01T20:05:11.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":1074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 28, 2026, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control."}],"balance_after":12367,"source":{"system":"sec-edgar","filing":"0000950170-25-061816","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000095017025061816/ownership.xml","form_type":"4"}},{"id":1163263,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T16:30:09.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 30, 2025, the Reporting Person was granted 62,500 Restricted Stock Units (the \"Award\").  The Award vests in equal monthly installments over the 12 months from the date of grant."}],"balance_after":67233,"source":{"system":"sec-edgar","filing":"0000950170-25-061115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017025061115/ownership.xml","form_type":"4"}},{"id":1506797,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-21T16:23:37.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":60000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-19","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-062931","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017024062931/ownership.xml","form_type":"4"}},{"id":1510692,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T16:38:42.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of\nStockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the\nCompany's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-061749","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000095017024061749/ownership.xml","form_type":"4"}},{"id":1531515,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-02T20:05:35.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":1218,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11293,"source":{"system":"sec-edgar","filing":"0000950170-24-052075","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/31791/000095017024052075/ownership.xml","form_type":"4"}},{"id":1531514,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-02T20:05:35.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock.  The grant of restricted stock units will fully vest on April 22, 2025, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control."}],"balance_after":10075,"source":{"system":"sec-edgar","filing":"0000950170-24-052075","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000095017024052075/ownership.xml","form_type":"4"}},{"id":1763574,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-10-06T18:21:24.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4016,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU (as defined in footnote 7 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Reflects the disposition of Issuer's restricted stock unit awards (each, a \"RSU\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was  canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Ordinary Shares subject to the RSUs vest on July 27, 2024."}],"balance_after":0,"derivative":{"expiration_date":"2024-07-27","underlying":"Ordinary Shares","underlying_shares":4016},"source":{"system":"sec-edgar","filing":"0001209191-23-052374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052374/doc4.xml","form_type":"4"}},{"id":1763573,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-06T18:21:24.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32161,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option (as defined in footnote 4 to this Form 4) is fully vested."}],"balance_after":0,"derivative":{"exercise_price":13.87,"expiration_date":"2028-05-02","underlying":"Ordinary Shares","underlying_shares":32161},"source":{"system":"sec-edgar","filing":"0001209191-23-052374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052374/doc4.xml","form_type":"4"}},{"id":1763572,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-06T18:21:24.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":52232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an \"Option\") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Option (as defined in footnote 4 to this Form 4) is fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.19,"expiration_date":"2027-08-01","underlying":"Ordinary Shares","underlying_shares":52232},"source":{"system":"sec-edgar","filing":"0001209191-23-052374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052374/doc4.xml","form_type":"4"}},{"id":1763571,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-10-06T18:21:24.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20279,"price":116.5,"value":2362503.5,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"9,349 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the disposition of ordinary shares of Horizon Therapeutics plc (\"Issuer\"), nominal value $0.0001 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the \"Transaction Agreement\"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. (\"Parent\"), and Pillartree Limited, a wholly owned subsidiary of Parent (\"Acquirer Sub\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $116.50 in cash (the \"Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-052374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052374/doc4.xml","form_type":"4"}},{"id":1763570,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-10-06T18:21:24.000Z","date":"2023-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25672,"price":116.5,"value":2990788.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"9,349 Ordinary Shares (as defined in footnote 2 of this Form 4) previously reported as held indirectly by Trust are held directly."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the disposition of ordinary shares of Horizon Therapeutics plc (\"Issuer\"), nominal value $0.0001 per share (\"Ordinary Shares\"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the \"Transaction Agreement\"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. (\"Parent\"), and Pillartree Limited, a wholly owned subsidiary of Parent (\"Acquirer Sub\"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the \"Scheme\") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the \"Effective Time\"), each outstanding Ordinary Share was converted into $116.50 in cash (the \"Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-052374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123052374/doc4.xml","form_type":"4"}},{"id":1808284,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-14T16:36:59.000Z","date":"2023-08-10","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant, subject to the Reporting Person's continuous service."}],"balance_after":15000,"derivative":{"exercise_price":1.36,"expiration_date":"2033-08-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-045646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919123045646/doc4.xml","form_type":"4"}},{"id":1821458,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-07-28T16:38:03.000Z","date":"2023-07-27","kind":"grant","planned":false,"acquired":true,"shares":4016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":4016,"derivative":{"exercise_date":"2024-07-27","expiration_date":"2024-07-27","underlying":"Ordinary shares","underlying_shares":4016},"source":{"system":"sec-edgar","filing":"0001209191-23-043695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123043695/doc4.xml","form_type":"4"}},{"id":1856934,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T16:55:24.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":1.45,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-036785","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919123036785/doc4.xml","form_type":"4"}},{"id":1890803,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-17T20:05:52.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":955,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":9098,"source":{"system":"sec-edgar","filing":"0000950170-23-022710","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/31791/000095017023022710/ownership.xml","form_type":"4"}},{"id":1890802,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-17T20:05:52.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock.  The grant of restricted stock units will fully vest on April 23, 2024, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months\nfollowing a change in control."}],"balance_after":8143,"source":{"system":"sec-edgar","filing":"0000950170-23-022710","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000095017023022710/ownership.xml","form_type":"4"}},{"id":1908235,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-02T19:34:27.000Z","date":"2023-04-28","kind":"exercise","planned":false,"acquired":false,"shares":3913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":0,"derivative":{"exercise_date":"2023-04-28","expiration_date":"2023-04-28","underlying":"Ordinary Shares","underlying_shares":3913},"source":{"system":"sec-edgar","filing":"0001209191-23-026758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123026758/doc4.xml","form_type":"4"}},{"id":1908234,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-05-02T19:34:27.000Z","date":"2023-04-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":1879,"price":111.16,"value":208869.64,"ownership":{"direct":true},"balance_after":16323,"source":{"system":"sec-edgar","filing":"0001209191-23-026758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123026758/doc4.xml","form_type":"4"}},{"id":1908233,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-05-02T19:34:27.000Z","date":"2023-04-28","kind":"exercise","planned":false,"acquired":true,"shares":3913,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"14,289 Ordinary Shares previously reported as indirectly held by Trust held directly."}],"balance_after":18202,"source":{"system":"sec-edgar","filing":"0001209191-23-026758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919123026758/doc4.xml","form_type":"4"}},{"id":2235498,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T16:15:15.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":90000,"derivative":{"exercise_price":0.27,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-22-035859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919122035859/doc4.xml","form_type":"4"}},{"id":2278836,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-09T20:05:29.000Z","date":"2022-05-06","kind":"grant","acquired":true,"shares":744,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7360,"source":{"system":"sec-edgar","filing":"0000899243-22-017244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924322017244/doc4.xml","form_type":"4"}},{"id":2278835,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-09T20:05:29.000Z","date":"2022-05-06","kind":"grant","acquired":true,"shares":610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 25, 2023, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control."}],"balance_after":6616,"source":{"system":"sec-edgar","filing":"0000899243-22-017244","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924322017244/doc4.xml","form_type":"4"}},{"id":2286427,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-02T18:12:29.000Z","date":"2022-04-29","kind":"exercise","acquired":false,"shares":4223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":0,"derivative":{"exercise_date":"2022-04-29","expiration_date":"2022-04-29","underlying":"Ordinary shares","underlying_shares":4223},"source":{"system":"sec-edgar","filing":"0001209191-22-026468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122026468/doc4.xml","form_type":"4"}},{"id":2286426,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-02T18:12:29.000Z","date":"2022-04-28","kind":"grant","acquired":true,"shares":3913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":3913,"derivative":{"exercise_date":"2023-04-28","expiration_date":"2023-04-28","underlying":"Ordinary shares","underlying_shares":3913},"source":{"system":"sec-edgar","filing":"0001209191-22-026468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122026468/doc4.xml","form_type":"4"}},{"id":2286425,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-05-02T18:12:29.000Z","date":"2022-04-29","kind":"tax_withholding","acquired":false,"shares":1658,"price":98.56,"value":163412.48,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":43917,"source":{"system":"sec-edgar","filing":"0001209191-22-026468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122026468/doc4.xml","form_type":"4"}},{"id":2286424,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-05-02T18:12:29.000Z","date":"2022-04-29","kind":"exercise","acquired":true,"shares":4223,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":45575,"source":{"system":"sec-edgar","filing":"0001209191-22-026468","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919122026468/doc4.xml","form_type":"4"}},{"id":2667776,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T16:46:59.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":40000,"derivative":{"exercise_price":0.9877,"expiration_date":"2031-06-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-040631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919121040631/doc4.xml","form_type":"4"}},{"id":2722254,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-10T21:17:29.000Z","date":"2021-05-07","kind":"grant","acquired":true,"shares":709,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6006,"source":{"system":"sec-edgar","filing":"0000899243-21-018992","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924321018992/doc4.xml","form_type":"4"}},{"id":2722253,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-10T21:17:29.000Z","date":"2021-05-07","kind":"grant","acquired":true,"shares":604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock.  The grant of restricted stock units will fully vest on April 26, 2022, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control."}],"balance_after":5297,"source":{"system":"sec-edgar","filing":"0000899243-21-018992","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924321018992/doc4.xml","form_type":"4"}},{"id":2734473,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-04-30T19:02:08.000Z","date":"2021-04-30","kind":"exercise","acquired":false,"shares":11098,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":0,"derivative":{"exercise_date":"2021-04-30","expiration_date":"2021-04-30","underlying":"Ordinary shares","underlying_shares":11098},"source":{"system":"sec-edgar","filing":"0001209191-21-029366","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919121029366/doc4.xml","form_type":"4"}},{"id":2734472,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-04-30T19:02:08.000Z","date":"2021-04-29","kind":"grant","acquired":true,"shares":4223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":4223,"derivative":{"exercise_date":"2022-04-29","expiration_date":"2022-04-29","underlying":"Ordinary shares","underlying_shares":4223},"source":{"system":"sec-edgar","filing":"0001209191-21-029366","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919121029366/doc4.xml","form_type":"4"}},{"id":2734471,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-30T19:02:08.000Z","date":"2021-04-30","kind":"tax_withholding","acquired":false,"shares":4357,"price":94.62,"value":412259.34,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":41352,"source":{"system":"sec-edgar","filing":"0001209191-21-029366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919121029366/doc4.xml","form_type":"4"}},{"id":2734470,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-04-30T19:02:08.000Z","date":"2021-04-30","kind":"exercise","acquired":true,"shares":11098,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":45709,"source":{"system":"sec-edgar","filing":"0001209191-21-029366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919121029366/doc4.xml","form_type":"4"}},{"id":3069585,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-08-04T17:08:41.000Z","date":"2020-08-02","kind":"exercise","acquired":false,"shares":8204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the restricted stock units vest in three equal annual installments on the anniversary of the grant date (August 2, 2017)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Ordinary shares","underlying_shares":8204},"source":{"system":"sec-edgar","filing":"0001209191-20-044741","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120044741/doc4.xml","form_type":"4"}},{"id":3069584,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-08-04T17:08:41.000Z","date":"2020-08-02","kind":"tax_withholding","acquired":false,"shares":3221,"price":61.19,"value":197092.99,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":34611,"source":{"system":"sec-edgar","filing":"0001209191-20-044741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120044741/doc4.xml","form_type":"4"}},{"id":3069583,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-08-04T17:08:41.000Z","date":"2020-08-02","kind":"exercise","acquired":true,"shares":8204,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":37832,"source":{"system":"sec-edgar","filing":"0001209191-20-044741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120044741/doc4.xml","form_type":"4"}},{"id":3104029,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T16:45:51.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":23250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":23250,"derivative":{"exercise_price":0.88,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":23250},"source":{"system":"sec-edgar","filing":"0001209191-20-037968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919120037968/doc4.xml","form_type":"4"}},{"id":3153781,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-12T20:07:08.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":1081,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4693,"source":{"system":"sec-edgar","filing":"0000899243-20-012810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924320012810/doc4.xml","form_type":"4"}},{"id":3153780,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-12T20:07:08.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":244,"price":92.2,"value":22496.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock.  The grant of restricted stock units will fully vest on April 27, 2021, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Restricted stock units were awarded in lieu of the reporting person's first 2020 quarterly cash retainer payment, with the number of restricted stock units determined by dividing the amount of the cash retainer payment by the Black-Scholes value of a restricted stock unit on the date the grant was made."}],"balance_after":3612,"source":{"system":"sec-edgar","filing":"0000899243-20-012810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924320012810/doc4.xml","form_type":"4"}},{"id":3153779,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-12T20:07:08.000Z","date":"2020-05-08","kind":"grant","acquired":true,"shares":922,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock.  The grant of restricted stock units will fully vest on April 27, 2021, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control."}],"balance_after":3368,"source":{"system":"sec-edgar","filing":"0000899243-20-012810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924320012810/doc4.xml","form_type":"4"}},{"id":3163634,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-05-04T17:35:30.000Z","date":"2020-05-02","kind":"exercise","acquired":false,"shares":15390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 2, 2019, the reporting person was granted 15,390 restricted stock units, vesting in full on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 2, 2019, the reporting person was granted 15,390 restricted stock units, vesting in full on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Ordinary shares","underlying_shares":15390},"source":{"system":"sec-edgar","filing":"0001209191-20-026895","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120026895/doc4.xml","form_type":"4"}},{"id":3163633,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-05-04T17:35:30.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":11098,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":11098,"derivative":{"exercise_date":"2021-04-30","expiration_date":"2021-04-30","underlying":"Ordinary shares","underlying_shares":11098},"source":{"system":"sec-edgar","filing":"0001209191-20-026895","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120026895/doc4.xml","form_type":"4"}},{"id":3163632,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-05-04T17:35:30.000Z","date":"2020-05-02","kind":"tax_withholding","acquired":false,"shares":6041,"price":35.62,"value":215180.42,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":29628,"source":{"system":"sec-edgar","filing":"0001209191-20-026895","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120026895/doc4.xml","form_type":"4"}},{"id":3163631,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-05-04T17:35:30.000Z","date":"2020-05-02","kind":"exercise","acquired":true,"shares":15390,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":35669,"source":{"system":"sec-edgar","filing":"0001209191-20-026895","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919120026895/doc4.xml","form_type":"4"}},{"id":3330891,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-12-26T08:54:35.000Z","date":"2019-12-24","kind":"grant","acquired":true,"shares":67700,"price":0.125,"value":8462.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":67700,"derivative":{"exercise_price":0.666,"exercise_date":"2019-12-24","expiration_date":"2024-12-24","underlying":"Common Stock","underlying_shares":67700},"source":{"system":"sec-edgar","filing":"0001209191-19-061857","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119061857/doc4.xml","form_type":"4"}},{"id":3330890,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A-2 Convertible Preferred Stock","published_at":"2019-12-26T08:54:35.000Z","date":"2019-12-24","kind":"grant","acquired":true,"shares":6770,"price":6.66,"value":45088.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The securities were acquired from the issuer pursuant to a Securities Purchase Agreement dated May 3, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder were approved by the Issuer's Board of Directors and an independent committee thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Class A-2 Convertible Preferred Stock have no expiration date and are convertible at any time at the election of the holder into shares of Common Stock without payment of further consideration.  Each share of Class A-2 Convertible Preferred Stock converts into 10 shares of Common Stock."}],"balance_after":6770,"derivative":{"underlying":"Common Stock","underlying_shares":67700},"source":{"system":"sec-edgar","filing":"0001209191-19-061857","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119061857/doc4.xml","form_type":"4"}},{"id":3362524,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-22T21:05:50.000Z","date":"2019-11-21","kind":"sale","acquired":false,"shares":1043,"price":90.67,"value":94568.81,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $90.66 to $90.68.  The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":2446,"source":{"system":"sec-edgar","filing":"0000899243-19-027947","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924319027947/doc4.xml","form_type":"4"}},{"id":3393487,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-15T16:49:30.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":46500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":46500,"derivative":{"exercise_price":0.64,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":46500},"source":{"system":"sec-edgar","filing":"0001209191-19-053175","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119053175/doc4.xml","form_type":"4"}},{"id":3447094,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-08-05T17:02:55.000Z","date":"2019-08-02","kind":"exercise","acquired":false,"shares":8203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the restricted stock units vest in three equal annual installments on the anniversary of the grant date (August 2, 2017)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":8204,"derivative":{"underlying":"Ordinary shares","underlying_shares":8203},"source":{"system":"sec-edgar","filing":"0001209191-19-044613","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119044613/doc4.xml","form_type":"4"}},{"id":3447093,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-08-05T17:02:55.000Z","date":"2019-08-02","kind":"tax_withholding","acquired":false,"shares":3220,"price":24.64,"value":79340.8,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":20279,"source":{"system":"sec-edgar","filing":"0001209191-19-044613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119044613/doc4.xml","form_type":"4"}},{"id":3447092,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-08-05T17:02:55.000Z","date":"2019-08-02","kind":"exercise","acquired":true,"shares":8203,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":23499,"source":{"system":"sec-edgar","filing":"0001209191-19-044613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119044613/doc4.xml","form_type":"4"}},{"id":3516522,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-05-21T16:44:03.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":29630,"price":0.125,"value":3703.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":29630,"derivative":{"exercise_price":1.08,"exercise_date":"2019-05-07","expiration_date":"2024-05-07","underlying":"Common Stock","underlying_shares":29630},"source":{"system":"sec-edgar","filing":"0001209191-19-031764","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119031764/doc4a.xml","form_type":"4/A","original_submission_date":"2019-05-08"}},{"id":3516521,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-21T16:44:03.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":29630,"price":1.08,"value":32000.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being amended to correct the transaction code. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated May 3, 2019 with a closing date of May 7, 2019.  The Securities Purchase Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors and an independent committee thereof."}],"balance_after":37849,"source":{"system":"sec-edgar","filing":"0001209191-19-031764","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119031764/doc4a.xml","form_type":"4/A","original_submission_date":"2019-05-08"}},{"id":3534909,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Purchase Warrant (Right to Buy)","published_at":"2019-05-08T17:15:09.000Z","date":"2019-05-07","kind":"purchase","acquired":true,"shares":29630,"price":0.125,"value":3703.75,"ownership":{"direct":true},"balance_after":29630,"derivative":{"exercise_price":1.08,"exercise_date":"2019-05-07","expiration_date":"2024-05-07","underlying":"Common Stock","underlying_shares":29630},"source":{"system":"sec-edgar","filing":"0001209191-19-028280","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119028280/doc4.xml","form_type":"4"}},{"id":3534908,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-08T17:15:09.000Z","date":"2019-05-07","kind":"purchase","acquired":true,"shares":29630,"price":1.08,"value":32000.4,"ownership":{"direct":true},"balance_after":37849,"source":{"system":"sec-edgar","filing":"0001209191-19-028280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119028280/doc4.xml","form_type":"4"}},{"id":3538018,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-05-06T17:46:35.000Z","date":"2019-05-03","kind":"exercise","acquired":false,"shares":15320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 3, 2018, the reporting person was granted 15,320 restricted stock units, vesting in full on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 3, 2018, the reporting person was granted 15,320 restricted stock units, vesting in full on the first anniversary of the grant date."}],"balance_after":0,"derivative":{"underlying":"Ordinary shares","underlying_shares":15320},"source":{"system":"sec-edgar","filing":"0001209191-19-027815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119027815/doc4.xml","form_type":"4"}},{"id":3538017,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-05-06T17:46:35.000Z","date":"2019-05-02","kind":"grant","acquired":true,"shares":15390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":15390,"derivative":{"exercise_date":"2020-05-02","underlying":"Ordinary shares","underlying_shares":15390},"source":{"system":"sec-edgar","filing":"0001209191-19-027815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119027815/doc4.xml","form_type":"4"}},{"id":3538016,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-06T17:46:35.000Z","date":"2019-05-03","kind":"tax_withholding","acquired":false,"shares":6014,"price":26.54,"value":159611.56,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":15296,"source":{"system":"sec-edgar","filing":"0001209191-19-027815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119027815/doc4.xml","form_type":"4"}},{"id":3538015,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-06T17:46:35.000Z","date":"2019-05-03","kind":"exercise","acquired":true,"shares":15320,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":21310,"source":{"system":"sec-edgar","filing":"0001209191-19-027815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919119027815/doc4.xml","form_type":"4"}},{"id":3545203,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-01T20:45:07.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":1043,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3489,"source":{"system":"sec-edgar","filing":"0000899243-19-011599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924319011599/doc4.xml","form_type":"4"}},{"id":3545202,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-01T20:45:07.000Z","date":"2019-04-30","kind":"grant","acquired":true,"shares":785,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock.  The grant of restricted stock units will fully vest on April 30, 2020, which is the first anniversary of the date on which the grant was made."}],"balance_after":2446,"source":{"system":"sec-edgar","filing":"0000899243-19-011599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924319011599/doc4.xml","form_type":"4"}},{"id":3690722,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Nonqualified Stock Option (right to buy)","published_at":"2019-01-22T09:58:55.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":14221,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option."}],"balance_after":0,"derivative":{"exercise_price":46.89,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":14221},"source":{"system":"sec-edgar","filing":"0001123292-19-000174","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000174/edgar.xml","form_type":"4"}},{"id":3690721,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Restricted Stock Units","published_at":"2019-01-22T09:58:55.000Z","date":"2019-01-22","kind":"disposition_to_issuer","acquired":false,"shares":8104,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of TESARO common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the \"Effective Time\") in exchange for a cash payment of $75.00 per share."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8104},"source":{"system":"sec-edgar","filing":"0001123292-19-000174","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000174/edgar.xml","form_type":"4"}},{"id":3690720,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-22T09:58:55.000Z","date":"2019-01-22","kind":"other","acquired":false,"shares":1279,"price":75,"value":95925.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation (\"Purchaser\") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales (\"Parent\"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation (\"TESARO\"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the \"Merger Agreement\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001123292-19-000174","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000112329219000174/edgar.xml","form_type":"4"}},{"id":3766325,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:32:11.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":4583,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The cancelled option vested in twelve equally monthly installments, such that the option would have been fully vested one year from the date of grant, or the date of the Company's next annual shareholder meeting, whichever occured first."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":8.76,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":4583},"source":{"system":"sec-edgar","filing":"0001209191-18-058341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919118058341/doc4.xml","form_type":"4"}},{"id":3766324,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:32:11.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The cancelled option provided for vesting in 12 equal monthly installments commencing on the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":8.52,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001209191-18-058341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919118058341/doc4.xml","form_type":"4"}},{"id":3766323,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-13T17:32:11.000Z","date":"2018-11-12","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On November 12, 2018, the issuer cancelled, pursuant to the issuer's option exchange program, the listed option.  In exchange for the options cancelled, the reporting person received the Restricted Stock Units reported above in Table I."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One third of the shares subject to the cancelled option would have vested on the one year anniversary of the date of grant and the balance of the shares would have vested in a series of 24 equal monthly installments thereafter, such that the option would have been fully vested on the third anniversary of the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":0,"derivative":{"exercise_price":17.4,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-18-058341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919118058341/doc4.xml","form_type":"4"}},{"id":3766322,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-13T17:32:11.000Z","date":"2018-11-12","kind":"grant","acquired":true,"shares":15833,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 12, 2018, the issuer canceled, pursuant to the issuer's option exchange program, the options listed below in Table II. In exchange for the options cancelled, the reporting person received Restricted Stock Units (RSUs) as reported in this Table I.  The RSUs vest ratably on a quarterly basis, such that the the RSUs are fully vested one year after the date of grant, subject to the reporting person's continuous service to Regulus through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Share numbers and exercise price reflect the 12-to-1 reverse stock split of the Issuer's common stock effective October 3, 2018."}],"balance_after":19625,"source":{"system":"sec-edgar","filing":"0001209191-18-058341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919118058341/doc4.xml","form_type":"4"}},{"id":3772186,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-07T21:06:00.000Z","date":"2018-11-06","kind":"sale","acquired":false,"shares":2206,"price":83.615,"value":184454.69,"ownership":{"direct":true},"balance_after":1661,"source":{"system":"sec-edgar","filing":"0000899243-18-028405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924318028405/doc4.xml","form_type":"4"}},{"id":3855017,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-08-02T18:50:14.000Z","date":"2018-08-02","kind":"exercise","acquired":false,"shares":8203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the restricted stock units vest in three equal annual installments on the anniversary of the grant date (August 2, 2017)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":16407,"derivative":{"underlying":"Ordinary shares","underlying_shares":8203},"source":{"system":"sec-edgar","filing":"0001209191-18-045090","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919118045090/doc4.xml","form_type":"4"}},{"id":3855016,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-08-02T18:50:14.000Z","date":"2018-08-02","kind":"tax_withholding","acquired":false,"shares":2213,"price":18.18,"value":40232.34,"ownership":{"direct":false,"nature":"By Trust"},"balance_after":5990,"source":{"system":"sec-edgar","filing":"0001209191-18-045090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919118045090/doc4.xml","form_type":"4"}},{"id":3855015,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-08-02T18:50:14.000Z","date":"2018-08-02","kind":"exercise","acquired":true,"shares":8203,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":8203,"source":{"system":"sec-edgar","filing":"0001209191-18-045090","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919118045090/doc4.xml","form_type":"4"}},{"id":3875023,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Restricted Stock Units","published_at":"2018-07-03T16:56:58.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":8104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of TESARO common stock."},{"field":"shares","element":"transactionShares","label":"F5","text":"This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the \"Original Form 4\") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the \"Original Form 4\") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the \"Original Form 4\") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4."}],"balance_after":8104,"derivative":{"underlying":"Common Stock","underlying_shares":8104},"source":{"system":"sec-edgar","filing":"0001104659-18-043867","document":"a4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918043867/a4a.xml","form_type":"4/A","original_submission_date":"2018-06-05"}},{"id":3875022,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Nonqualified Stock Option (right to buy)","published_at":"2018-07-03T16:56:58.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":14221,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the \"Original Form 4\") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the \"Original Form 4\") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"This amendment is being filed to amend the Form 4 filed by the reporting person on June 5, 2018 (the \"Original Form 4\") for the sole purpose of correcting the numbers of derivative securities acquired as reported in column 5 of Table II of the Original Form 4, the numbers of shares underlying securities as reported in column 7 of Table II of the Original Form 4, and the numbers of derivative securities beneficially owned following the reported transactions as reported in column 9 of Table II of the Original Form 4."}],"balance_after":14221,"derivative":{"exercise_price":46.89,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":14221},"source":{"system":"sec-edgar","filing":"0001104659-18-043867","document":"a4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918043867/a4a.xml","form_type":"4/A","original_submission_date":"2018-06-05"}},{"id":3875021,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-03T16:56:58.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":1279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person has elected to receive common stock in lieu of cash for board retainers and fees otherwise payable in cash."}],"balance_after":1279,"source":{"system":"sec-edgar","filing":"0001104659-18-043867","document":"a4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918043867/a4a.xml","form_type":"4/A","original_submission_date":"2018-06-05"}},{"id":3905308,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Restricted Stock Units","published_at":"2018-06-05T17:08:26.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":4052,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of TESARO common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":4052,"derivative":{"underlying":"Common Stock","underlying_shares":4052},"source":{"system":"sec-edgar","filing":"0001104659-18-038346","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918038346/a4.xml","form_type":"4"}},{"id":3905307,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Nonqualified Stock Option (right to buy)","published_at":"2018-06-05T17:08:26.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":7209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in three annual installments beginning on June 1, 2019, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":7209,"derivative":{"exercise_price":46.89,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":7209},"source":{"system":"sec-edgar","filing":"0001104659-18-038346","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918038346/a4.xml","form_type":"4"}},{"id":3905306,"issuer":{"id":160894,"kind":"organization","name":"TESARO, Inc.","symbol":"TSRO"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-05T17:08:26.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":1279,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person has elected to receive common stock in lieu of cash for board retainers and fees otherwise payable in cash."}],"balance_after":1279,"source":{"system":"sec-edgar","filing":"0001104659-18-038346","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491576/000110465918038346/a4.xml","form_type":"4"}},{"id":3904512,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-05T16:32:08.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in twelve equally monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first."}],"balance_after":55000,"derivative":{"exercise_price":0.73,"expiration_date":"2028-05-31","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-18-035708","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919118035708/doc4.xml","form_type":"4"}},{"id":3923612,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-21T16:44:17.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in twelve equally monthly installments, such that the option will be fully vested one year from the date of grant, or the date of the Company's 2019 annual shareholder meeting, whichever occurs first."}],"balance_after":75000,"derivative":{"exercise_price":0.71,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-18-031898","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919118031898/doc4.xml","form_type":"4"}},{"id":3944320,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-05-07T17:07:26.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":15320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer."}],"balance_after":15320,"derivative":{"exercise_date":"2019-05-03","underlying":"Ordinary shares","underlying_shares":15320},"source":{"system":"sec-edgar","filing":"0001209191-18-028370","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919118028370/doc4.xml","form_type":"4"}},{"id":3944319,"issuer":{"id":109157,"kind":"organization","name":"Horizon Therapeutics Public Ltd Co","symbol":"HZNP"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-07T17:07:26.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":32161,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments from the date of grant."}],"balance_after":32161,"derivative":{"exercise_price":13.87,"expiration_date":"2028-05-02","underlying":"Ordinary shares","underlying_shares":32161},"source":{"system":"sec-edgar","filing":"0001209191-18-028370","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1492426/000120919118028370/doc4.xml","form_type":"4"}},{"id":3946732,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-04T20:06:18.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":1386,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3867,"source":{"system":"sec-edgar","filing":"0000899243-18-011501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924318011501/doc4.xml","form_type":"4"}},{"id":3946731,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-04T20:06:18.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":1043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock.  The grant of restricted stock units will fully vest on May 3, 2019, which is the first anniversary of the date on which the grant was made."}],"balance_after":2481,"source":{"system":"sec-edgar","filing":"0000899243-18-011501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924318011501/doc4.xml","form_type":"4"}},{"id":4140170,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-06T19:39:46.000Z","date":"2017-12-04","kind":"grant","acquired":true,"shares":60674,"price":0.89,"value":53999.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted Stock Units (RSUs) issued in lieu of 2018 annual retainer and meeting fees of $54,000.  The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus."}],"balance_after":60674,"source":{"system":"sec-edgar","filing":"0001209191-17-064269","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919117064269/doc4.xml","form_type":"4"}},{"id":4161629,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-16T21:05:34.000Z","date":"2017-11-15","kind":"grant","acquired":true,"shares":820,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1438,"source":{"system":"sec-edgar","filing":"0000899243-17-026587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924317026587/doc4.xml","form_type":"4"}},{"id":4161628,"issuer":{"id":3382,"kind":"organization","name":"REVVITY, INC.","symbol":"RVTY"},"owners":[{"id":48571,"kind":"person","name":"Witz Pascale","position":1,"cik":"0001703723","reported_name":"Witz Pascale","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-11-16T21:05:34.000Z","date":"2017-11-15","kind":"grant","acquired":true,"shares":618,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock.  The grant of restricted stock units will fully vest on November 15, 2018, which is the first anniversary of the date on which the grant was made."}],"balance_after":618,"source":{"system":"sec-edgar","filing":"0000899243-17-026587","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/31791/000089924317026587/doc4.xml","form_type":"4"}}],"next_cursor":"2017-11-16T21:05:34.000000Z,4161628"}